We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
AbbVie has unveiled new data showing high and durable undetectable minimal residual disease rates in patients with chronic lymphocytic leukaemia treated with venetoclax in combination with rituximab.